tetano
Editor, Senior Moderator
Neurol Neuroimmunol Neuroinflamm
. 2025 May;12(3):e200393.
doi: 10.1212/NXI.0000000000200393. Epub 2025 Apr 25. SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update
Tobias Monschein[SUP] 1 2 3 [/SUP], Tobias Zrzavy[SUP] 1 2 [/SUP], Paulus S Rommer[SUP] 1 2 [/SUP], Sven G Meuth[SUP] 4 [/SUP], Andrew Chan[SUP] 3 [/SUP], Thomas Berger[SUP] 1 2 [/SUP], Hans-Peter Hartung[SUP] 1 2 4 5 6 [/SUP]
Affiliations
The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.[SUP]1-3[/SUP] Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.[SUP]4[/SUP] In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.
. 2025 May;12(3):e200393.
doi: 10.1212/NXI.0000000000200393. Epub 2025 Apr 25. SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update
Tobias Monschein[SUP] 1 2 3 [/SUP], Tobias Zrzavy[SUP] 1 2 [/SUP], Paulus S Rommer[SUP] 1 2 [/SUP], Sven G Meuth[SUP] 4 [/SUP], Andrew Chan[SUP] 3 [/SUP], Thomas Berger[SUP] 1 2 [/SUP], Hans-Peter Hartung[SUP] 1 2 4 5 6 [/SUP]
Affiliations
- PMID: 40279527
- DOI: 10.1212/NXI.0000000000200393
The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.[SUP]1-3[/SUP] Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.[SUP]4[/SUP] In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.